review weak vaccin busi sweep away earn
green cross gcc op miss consensu mainli
order cut flu vaccin export cse bn vs actual bn
addit evalu loss equiti invest bn
weigh bottom-lin earn
vaccin gcc lost share paho flu vaccin market
due new entrant asp eros yoy result
expect weak sustain domest
weak due competit zostavax suppli constraint
gardasil manag expect improv suppli
plasma deriv export improv new order kick-in
ivig china export resumpt albumin domest sale
remain solid thank price hike sinc
maintain outperform vaccin core busi
remain solid led plasma busi compani remain
track despit weak revis ep
reflect flu vaccin weak cut tp
await fda ivig approv
estimate pot chg tp
 chang prev ep
note found green cross corpor engag manufactur sale
medicin specialis plasma-deriv recombin protein vaccin therapeut
antibodi use field oncolog infecti diseas
click detail financi
reviewearn shock led vaccin busi
green cross gcc op miss consensu mainli order
cut flu vaccin export cse bn vs actual bn
volum asp seem impact addit
evalu loss equiti invest bn korean biotech
compani weigh bottom-lin earn book
op-lin
vaccin account sale mix
earn driver sinc thank export paho pan american
health organis help improv utilis rate slow
season oper weak yoy gcc
lost share paho flu vaccin bid market flu vaccin export
sale mix due new entrant least four player total vs
two asp eros yoy vs yoy result
understand volum impact larger yoy export
declin yoy expect weak sustain
given anticip volume/asp loss note gcc plan off-set
weak expand export mix varicella vaccin mix
expect outgrow flu vaccin domest
vaccin mix weak due competit zostavax mix
suppli constraint gadasil mix manag expect
improv suppli thank import normalis merck
plasma deriv biggest compon gcc mix
also steadi busi oper robust yoy
export improv new order kick-in ivig mix china
export resumpt albumin mix sustain
domest sale remain solid thank price hike ivig/albumin
mix sinc respect
figur earn revisionfactor weak vaccin export
 flu vaccin paho pan-american organ
export
outperform wait fda approv ivig
view weaker earn outlook driven share
price alreadi vaccin core busi remain solid led
plasma busi think earn remain
track despit weak revis ep
reflect flu vaccin weak cut export
estim cut tp await fda ivig approv
given resubmiss late-march accord
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
compani mention price
ray certifi view express report accur reflect person view subject compani secur
part compens directli indirectli relat specif recommend view express report
price rate histori green cross corp
signifi initi assumpt coverag
price rate histori merck co inc mrk
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attractiv neutral less attract
underperform least attract invest opportun octob canadian well european rate base stock total return
rel analyst coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti curren share price rel
attract stock total return potenti within analyst coverag univers australian new zealand stock expect total return calcul
includ roll dividend yield outperform rate assign greater equal under-perform less
equal neutral may assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform under-perform rate overlap neutral threshold betw en
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat compani
time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view
equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat
sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral nd under-perform close correspond
